Genocea Biosciences Commences Public Offering Of Common Stock
7/14/2014 1:32:08 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced that it has commenced an underwritten public offering of 3,400,000 shares of its common stock. All the shares in the offering will be sold by Genocea.
Help employers find you! Check out all the jobs and post your resume.
comments powered by